Building an Integrated Biopharma Company: Crucell (A) Harvard Case Solution & Analysis

In a sign of national pride as well as the Netherlands, Crucell had become the largest biopharma firm by 2009. The case traces the development of the company from a University spin-off into a fully-incorporated business. Crucell has achieved success mainly in vaccine space, and started to draw the attention of much larger pharmaceutical companies.

These relationships may additionally challenge the liberty of Crucell, while there clearly was much allure to working with these firms. This dilemma is emphasized by the decision whether to associate with businesses that needed ownership of 10% to 20% of business advancement deals.

PUBLICATION DATE: February 13, 2015 PRODUCT #: 815085-HCB-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

Building an Integrated Biopharma Company: Crucell (A) Case Solution Other Similar Case Solutions like

Building an Integrated Biopharma Company: Crucell (A)

Share This